Source: BioPharma-Reporter

TechnoVax: Collaborative VLP tech bolsters COVID-19 vaccine development

VLP platform using structural elements of coronavirus and modified surface spike molecules could be an âidealâ for COVID-19 vaccine development.

Read full article »
TechnoVax's Competitors | TechnoVax's News | TechnoVax's Financials
Stay up-to-date with the latest news on TechnoVax
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
CEO Avatar

President & CEO

Jose Galarza

CEO Approval Rating

69/100

Read more
Stay up-to-date with the latest news on TechnoVax